Published in Curr Opin Nephrol Hypertens on November 01, 2007
Progression of pediatric CKD of nonglomerular origin in the CKiD cohort. Clin J Am Soc Nephrol (2015) 0.90
A predictive model of progression of CKD to ESRD in a predialysis pediatric interdisciplinary program. Clin J Am Soc Nephrol (2014) 0.82
Proteinuria and progression of pediatric chronic kidney disease: lessons from recent clinical studies. Pediatr Nephrol (2016) 0.78
Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med (2012) 9.46
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int (2004) 4.51
An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int (2011) 3.96
Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation (2004) 3.78
Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol (2007) 2.61
Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med (2003) 2.45
The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int (2003) 2.43
A meta-analysis of hemodialysis catheter locking solutions in the prevention of catheter-related infection. Am J Kidney Dis (2008) 2.38
Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study. Clin J Am Soc Nephrol (2006) 2.37
Comparison of different measures of urinary protein excretion for prediction of renal events. J Am Soc Nephrol (2010) 2.22
Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial. Hypertension (2011) 2.05
Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant (2009) 2.02
Chemokine receptor polymorphism and risk of acute rejection in human renal transplantation. J Am Soc Nephrol (2002) 1.98
The clinical importance of nephron mass. J Am Soc Nephrol (2010) 1.94
Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease. Clin J Am Soc Nephrol (2007) 1.92
Low birth weight, nephron number, and kidney disease. Kidney Int Suppl (2005) 1.83
Adult hypertension and kidney disease: the role of fetal programming. Hypertension (2006) 1.82
Effect of fetal and child health on kidney development and long-term risk of hypertension and kidney disease. Lancet (2013) 1.73
Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE). J Renin Angiotensin Aldosterone Syst (2012) 1.68
Why is proteinuria an ominous biomarker of progressive kidney disease? Kidney Int Suppl (2004) 1.58
Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. Kidney Int (2004) 1.48
Hypertonic glucose-based peritoneal dialysate is associated with higher blood pressure and adverse haemodynamics as compared with icodextrin. Nephrol Dial Transplant (2005) 1.43
From secondary to primary prevention of progressive renal disease: the case for screening for albuminuria. Kidney Int (2004) 1.32
Prevalence and associations of limited health literacy in chronic kidney disease: a systematic review. Nephrol Dial Transplant (2012) 1.24
Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults. Nat Clin Pract Nephrol (2008) 1.19
Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes. An Asian perspective from the RENAAL Study. Diabetes Care (2004) 1.15
ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy. J Am Soc Nephrol (2008) 1.12
Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation. Diabetes Care (2003) 1.12
Reduced baroreflex sensitivity is associated with increased vascular calcification and arterial stiffness. Nephrol Dial Transplant (2005) 1.11
Skin autofluorescence and the association with renal and cardiovascular risk factors in chronic kidney disease stage 3. Clin J Am Soc Nephrol (2011) 1.09
Hepatitis B and C infection in haemodialysis patients in Libya: prevalence, incidence and risk factors. BMC Infect Dis (2012) 1.08
Automated peritoneal dialysis has significant effects on systemic hemodynamics. Perit Dial Int (2006) 1.02
Risk profile in chronic kidney disease stage 3: older versus younger patients. Nephron Clin Pract (2011) 1.02
Online conductivity monitoring: validation and usefulness in a clinical trial of reduced dialysate conductivity. ASAIO J (2005) 1.01
Anthropomorphic measurements that include central fat distribution are more closely related with key risk factors than BMI in CKD stage 3. PLoS One (2012) 1.01
Development of a formula for estimation of sodium intake from spot urine in people with chronic kidney disease. Nephron Clin Pract (2014) 1.00
Suboptimal blood pressure control in chronic kidney disease stage 3: baseline data from a cohort study in primary care. BMC Fam Pract (2013) 1.00
How to measure proteinuria? Curr Opin Nephrol Hypertens (2008) 0.99
Analysis of metabolic parameters as predictors of risk in the RENAAL study. Diabetes Care (2003) 0.97
Renoprotective effects of renin-angiotensin-system inhibitors. Lancet (2006) 0.96
Nephropathy in Fabry disease: the importance of early diagnosis and testing in high-risk populations. Nephrol Dial Transplant (2009) 0.96
Assessment of haemodialysis adequacy by ionic dialysance: intra-patient variability of delivered treatment. Nephrol Dial Transplant (2003) 0.95
Importance of baseline distribution of proteinuria in renal outcomes trials: lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study. J Am Soc Nephrol (2005) 0.95
Tissue-advanced glycation end product concentration in dialysis patients. Clin J Am Soc Nephrol (2009) 0.95
Analysis of factors associated with variability in haemodialysis adequacy. Nephrol Dial Transplant (2004) 0.90
Renal Association Clinical Practice Guideline on detection, monitoring and management of patients with CKD. Nephron Clin Pract (2011) 0.90
Effects of acetate-free double-chamber hemodiafiltration and standard dialysis on systemic hemodynamics and troponin T levels. ASAIO J (2006) 0.88
Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies. Am J Cardiol (2005) 0.88
Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetes. Diabetes Care (2006) 0.88
The renoprotective effects of structured care in a clinical trial setting in type 2 diabetic patients with nephropathy. Nephrol Dial Transplant (2004) 0.88
Combination ACEI and ARB therapy: additional benefit in renoprotection? Curr Opin Nephrol Hypertens (2002) 0.87
Fetal programming of adult kidney disease: cellular and molecular mechanisms. Clin J Am Soc Nephrol (2007) 0.87
Hemoglobin variability with epoetin beta and continuous erythropoietin receptor activator in patients on peritoneal dialysis. Perit Dial Int (2011) 0.87
Determinants of arterial stiffness in chronic kidney disease stage 3. PLoS One (2013) 0.86
Low nephron number and its clinical consequences. Rambam Maimonides Med J (2011) 0.85
Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results. J Am Soc Nephrol (2004) 0.85
Losartan and end-organ protection--lessons from the RENAAL study. Clin Cardiol (2005) 0.83
Comparison of progressive conductivity reduction with diacontrol and standard dialysis. ASAIO J (2007) 0.82
Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies. J Hypertens (2007) 0.82
Determinants of survival in patients receiving dialysis in Libya. Hemodial Int (2012) 0.82
Preventing catheter related infections in haemodialysis patients. Curr Opin Nephrol Hypertens (2006) 0.81
Chronic kidney disease 10 years on: what have we learned? Curr Opin Nephrol Hypertens (2012) 0.81
Adherence of tunnelled haemodialysis catheter to superior vena caval stent: successful percutaneous removal. Nephrol Dial Transplant (2003) 0.80
Socio-economic disparities in the distribution of cardiovascular risk in chronic kidney disease stage 3. Nephron Clin Pract (2013) 0.80
Strategies to retard the progression of chronic kidney disease. Med Clin North Am (2005) 0.80
Impact of the supplementation of kidney mass on blood pressure and progression of kidney disease. Nephrol Dial Transplant (2004) 0.79
Provision and quality of dialysis services in Libya. Hemodial Int (2011) 0.79
Natural history of skeletal muscle mass changes in chronic kidney disease stage 4 and 5 patients: an observational study. PLoS One (2013) 0.79
Epidemiology and aetiology of dialysis-treated end-stage kidney disease in Libya. BMC Nephrol (2012) 0.79
The impact of losartan on the lifetime incidence of end-stage renal disease and costs in patients with type 2 diabetes and nephropathy. Pharmacoeconomics (2006) 0.78
Dialysis delayed is death prevented: a clinical perspective on the RENAAL study. Kidney Int (2003) 0.78
Tissue advanced glycation end product deposition after kidney transplantation. Nephron Clin Pract (2013) 0.78
Vascular access in patients receiving hemodialysis in Libya. J Vasc Access (2013) 0.78
Baseline predictors of end-stage renal disease risk in patients with type 2 diabetes and nephropathy: new lessons from the RENAAL Study. Kidney Int Suppl (2005) 0.78
Losartan in patients with type 2 diabetes and proteinuria: observations from the RENAAL Study. Kidney Int Suppl (2002) 0.78
Long Term Outcomes after Acute Kidney Injury: Lessons from the ARID Study. Nephron (2015) 0.77
Impact of renin angiotensin system blockade on renal function in health and disease: an end or a beginning? Semin Nephrol (2004) 0.77
Predicting renal risk in the general population: do we have the right formula? Clin J Am Soc Nephrol (2011) 0.77
Use of online conductivity monitoring to study sodium mass balance in chronic haemodialysis patients: prospects for treatment individualisation. Kidney Blood Press Res (2011) 0.76
Length of interdialytic interval influences serum calcium and phosphorus concentrations. Nephrol Dial Transplant (2005) 0.76
Primary and secondary prevention of chronic kidney disease. J Hypertens (2005) 0.76
Multimorbidity in people with chronic kidney disease: implications for outcomes and treatment. Curr Opin Nephrol Hypertens (2016) 0.76
Effect of LDL cholesterol and treatment with losartan on end-stage renal disease in the RENAAL study. Diabetes Care (2007) 0.76
Introduction to Focus on Fabry nephropathy: biomarkers, progression, and disease severity. Clin J Am Soc Nephrol (2009) 0.75
Aliskiren in type 2 diabetes and cardiorenal end points. N Engl J Med (2013) 0.75
Preventing microalbuminuria in type 2 diabetes. N Engl J Med (2005) 0.75
Dual renin-angiotensin system blockade and kidney disease. J Am Coll Cardiol (2009) 0.75
Correction: The Association between Polyclonal Combined Serum Free Light Chain Concentration and Mortality in Individuals with Early Chronic Kidney Disease. PLoS One (2015) 0.75
Losartan: lessons learned from the RENAAL study. Expert Opin Pharmacother (2006) 0.75
Imaging and assessment of vascular calcification in chronic kidney disease patients. Curr Opin Nephrol Hypertens (2004) 0.75
Proteinuria: new information from an old friend. Curr Opin Nephrol Hypertens (2003) 0.75
Sodium MRI: a new frontier in imaging in nephrology. Curr Opin Nephrol Hypertens (2017) 0.75
An unusual case of renovascular hypertension-renal artery stenosis of a pelvic kidney with aberrant blood supply. Nephrol Dial Transplant (2005) 0.75
Continuous online monitoring of ionic dialysance allows modification of delivered hemodialysis treatment time. Hemodial Int (2006) 0.75